Evidence map›Paper›PMID 40541082›Full record

ArticleThe International journal on drug policy2025

Linkage to hepatitis C virus care in a binational cohort study of People who inject drugs on the U.S.-Mexico border.

Bo Shan Go, Daniela Abramovitz, Irina Artamonova, Alicia Harvey-Vera, Natasha Martin, Gudelia Rangel, Christian B Ramers, Samantha Tweeten, Winston Tilghman, Steffanie A Strathdee and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The International journal on drug policy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Bo Shan GoUniversity of Amsterdam, Amsterdam University Medical Centre, the Netherlands.
Daniela AbramovitzDivision of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla, CA, United States.
Irina ArtamonovaDivision of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla, CA, United States.
Alicia Harvey-VeraDivision of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla, CA, United States; US.-Mexico Border Health Commission, Tijuana, Baja California, Mexico.
Natasha MartinDivision of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla, CA, United States.
Gudelia RangelEl Colegio de la Frontera Norte, Tijuana, Baja California, Mexico; Laura Rodriguez Research Institute, Family Health Centers of San Diego, San Diego, CA, United States.
Christian B RamersDivision of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla, CA, United States; Laura Rodriguez Research Institute, Family Health Centers of San Diego, San Diego, CA, United States; Gilead Sciences, Foster City, CA, United States.
Samantha TweetenEpidemiology and Immunization Services Branch, Department of Public Health Services, County of San Diego Health & Human Services Agency. San Diego, CA, United States.
Winston TilghmanHIV, STD and Hepatitis Branch, Department of Public Health Services, County of San Diego Health & Human Services Agency. San Diego, CA, United States.
Steffanie A StrathdeeDivision of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla, CA, United States.
Robert G DeissDivision of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla, CA, United States. Electronic address: rgdeiss@health.ucsd.edu.

Funding

Ethno-epidemiology of HCV, HIV and Overdose associated with Drug Marketsand Drug TourismR01DA049644 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI STRATHDEE, STEFFANIE A. · 2020 to 2024
$8.2M
Epidemiology of HIV and Hepatitis C Among Injecting Drug Users in TijuanaR01DA019829 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI STRATHDEE, STEFFANIE A. · 2005 to 2009
$2.9M
Optimizing HIV prevention portfolios targeting people who inject drugs using dynamic economic modelingR01AI147490 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MARTIN, NATASHA · 2019 to 2022
$2.3M
NIAID NIH HHS R01 AI147490NIDA NIH HHS R01 DA019829NIDA NIH HHS R01 DA049644
6 · The paper itself

Abstract

backgroundPeople who inject drugs (PWID) experience high rates of Hepatitis C Virus (HCV) infection in the U.S.-Mexico border region, but their care continuum is poorly characterized.

methodsWe analysed the HCV care continuum (linkage to care, initiation and completion of treatment) in a cohort of PWID in Tijuana, Mexico and San Diego. We also used multivariable Poisson regression to identify factors associated with linkage to HCV care among PWID in San Diego and Tijuana who reported prior HCV diagnosis.

resultsAmong 133 PWID with active HCV infection in San Diego, 50.4 %, 16 % and 14.3 % reported prior awareness of their diagnosis; linkage to care and treatment completion; corresponding proportions for 21 PWID in Tijuana were 19 %, 14.3 % and 0 %. In multivariable analysis, factors independently associated with increased linkage to HCV care included receiving medication for opioid use disorder (MOUD) (Adjusted Prevalence Ratio [adjPR] 1.38; 95 % CI: 1.23-1.54) and HIV-seropositivity (adjPR 1.87 (95 %CI: 1.32-2.66). Tijuana residency (adjPR: 0.73; 95 % CI: 0.70-0.75) and younger age (adjPR 0.94 per 5-year age decrease; 95 % CI: 0.89-0.99) were independently associated with decreased linkage to care. Among PWID with a prior HCV diagnosis, 52.6 % and 40.7 % reported linkage to care in San Diego and Tijuana respectively.

conclusionsOur study shows poor linkage to HCV-related care among PWID in both San Diego and Tijuana, along with low treatment completion. MOUD programs could be an efficient touchpoint to improve access to HCV care.

Indexed as

Continuity of Patient CareHepatitis CSubstance Abuse, IntravenousAdultCaliforniaCohort StudiesFemaleHealth Services AccessibilityHumansMaleMexicoMiddle AgedOpioid-Related DisordersUnited StatesDrug useHepatitis C virusHIVOpiate substitution treatmentSubstance abuse, Intravenous

Identifiers

PMID40541082
PMCPMC12930412

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.